The European Association for the Study of Obesity (EASO) framework may offer a more sensitive measure of obesity than ...

Key messages • There is enough evidence to support the finding that extreme obesity (BMI > 40 kg/m 2) increases the chance of a person dying, requiring a breathing tube, being hospitalised, and being ...

A WHO-backed study reveals that overweight postmenopausal women with heart disease face a 31 per cent higher breast cancer ...

Losing weight isn’t always winning at health, say experts challenging the long-standing obsession with BMI and dieting. New ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

For years, people living with obesity have been given the same basic advice: eat less, move more. But while this mantra may ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...

Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% higher in ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

Rhythm Pharma (RYTM) stock gains as the company's experimental therapy bivamelagon shows promise in Phase 2 trial for rare acquired hypothalamic obesity. Read more here.